HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With AE Reporting Push, FDA Emphasizes Importance Of Cosmetic Safety

This article was originally published in The Rose Sheet

Executive Summary

FDA hopes a campaign promoting its adverse event reporting program for cosmetics will lead to increased consumer participation, which could put further pressure on industry to ensure the safety of their products.

You may also be interested in...

Cosmetic Adverse Event Reports Spiked 56% In Fiscal 2014 – FDA

According to FDA’s Office of Cosmetics and Colors, the number of cosmetic adverse events reported to the agency reached 491 in fiscal 2014, a 56% increase over fiscal 2013. FDA reps say the agency’s data can be deceptive and the total number likely would be higher if cosmetic adverse-event reporting were mandatory.

FDA Cosmetics Update: 2013 AE Reports Tallied, 2014 Research Targeted

FDA says cosmetic-related adverse events were down in fiscal 2013, but suggests the decline may be due to a falloff in agency outreach and lower consumer awareness. The agency is focused on trace contaminants, with guidance in the works on lipstick lead, and aims to release its final guidance on cosmetic nanomaterials in the coming months, according to Linda Katz, director of FDA’s cosmetics office.

Cosmetics Adverse Events Reported To FDA Increase 35% In FY 2012

The number of adverse events associated with cosmetics reported to FDA rose by nearly 100 between fiscal 2011 and 2012. The rise follows a push by the agency to increase awareness of the reporting program, but FDA cautions that may not solely be responsible for the higher numbers.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts